Table of Contents Table of Contents
Previous Page  34 / 42 Next Page
Information
Show Menu
Previous Page 34 / 42 Next Page
Page Background

34

Mutation

Status

N

Med OS FOLFIRI+

Placebo

Med OS FOLFIRI+

Aflibercept

HR 95%

CI

Interaction

( p-value)

KRAS ex2

WT

281

11.6

14.9

0.74 (0.56-0.99)

p=0.38

Mut

201

10.6

12.6

0.90 (0.65-1.24)

ExtRAS

WT

218

11.7

16.0

0.70 (0.50-0.97)

p=0.13

Mut

264

11.2

12.6

0.93 (0.70-1.23)

Extraido de Wirapati, P. et al DOI 10.1200/JCO.2017.35.15_suppl.3538

Journal of Clinical Oncology

35, no. 15_suppl (May 2017)

Aflibercept es eficaz en los pacientes de 2L de CCRm, independientemente del estado

mutacional del RAS (

p test de interacción negativo

)